Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Palisade Bio's annualizedGross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil.
Palisade Bio's average Total Assets over the quarter that ended in Mar. 2024 was $13.35 Mil. Therefore, Palisade Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.
Palisade Bio Gross-Profit-to-Asset % Historical Data
The historical data trend for Palisade Bio's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Palisade Bio's Gross-Profit-to-Asset %
For the Biotechnology subindustry, Palisade Bio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Palisade Bio's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Palisade Bio's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Palisade Bio's Gross-Profit-to-Asset % falls into.
Palisade Bio Gross-Profit-to-Asset % Calculation
Palisade Bio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Palisade Bio Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Palisade Bio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PALI has been successfully added to your 